Biomedtracker：2026年JPM医疗健康大会前瞻报告：重构未来（英文版）（26页）.pdf

1、RETHINKING NEW WAYS THE WAY OF THE FUTURE#JPM2026 PREVIEW REPORT#JPM2026 Preview Report 2 Biomedtracker JPM2026 Preview Copyright 2026 AI-Powered Biotech Innovation:From Promise to Proof Foreword by Deepali Suri,President,ICON Biotech Biotech is entering a pivotal phase where artificial intelligence

2、(AI)is no longer just a catalystits becoming the backbone of modern drug development.In 2025,we saw a surge in AI-native biotech startups,deeper integration of machine learning into clinical trial design,and the first wave of AI-discovered molecules entering human trials.These milestones mark a shif

3、t from theoretical potential to tangible progress.Yet,as innovation accelerates,so do the challenges.Financial constraints,talent shortages,and evolving regulatory frameworks,continue to impact biotechs ability to scale.For emerging companies,navigating these complexities while maintaining scientifi

4、c momentum is a perpetual challenge.One of the most dynamic developments in the past year has been the rise of Chinese biotech companies on the global stage.With over a third of therapeutic molecules acquired by global pharma in 2025 originating from China,the landscape is shifting rapidly.ICON is a

5、ctively engaged in supporting cross-border collaboration,helping biotech companies navigate regulatory,operational,and cultural complexities to unlock global potential.ICON remains committed to supporting biotech organizations through this transformation.Our flexible partnership models,deep therapeu

6、tic expertise,and global infrastructure enable companies to de-risk development and accelerate timelines.ICON Biotech,our dedicated division for emerging and mid-sized biotechs,offers tailored solutions that combine operational agility with strategic insightempowering our partners to focus on innova